Optimization and scale-up of Wharton's jelly-derived mesenchymal stem cells for clinical applications  by Nekanti, Usha et al.
ava i l ab l e a t www.sc i enced i r ec t . com
www.e l sev i e r . com/ l oca te / sc r
Stem Cell Research (2010) 5, 244–254REGULAR ARTICLE
Optimization and scale-up of Wharton's jelly-derived
mesenchymal stem cells for clinical applications
Usha Nekanti a, Lipsa Mohanty a, Parvathy Venugopal a,
Sudha Balasubramanian a, Satish Totey b, Malancha Ta c,⁎a Stempeutics Research Pvt. Ltd, Manipal Hospital, Bangalore, India
b Stempeutics Research Malaysia Sdn Bhd, Kuala Lumpur, Malaysia
c Manipal Institute of Regenerative Medicine, Manipal University, Bangalore, IndiaReceived 31 March 2010; received in revised form 23 August 2010; accepted 24 August 2010Abstract MSCs are promising candidates for stem cell therapy and regenerative medicine. Umbilical cord is the easiest
obtainable biological source of MSCs and the Wharton's jelly of the umbilical cord is a rich source of fetus-derived stem cells.
However, the use of MSCs for therapeutic application is based on their subsequent large-scale in vitro expansion. A fast and
efficient protocol for generation of large quantities of MSCs is required to meet the clinical demand and biomedical research
needs. Here we have optimized conditions for scaling up of WJ-MSCs. Low seeding density along with basic fibroblast growth
factor (bFGF) supplementation in the growth medium, which is DMEM-KO, resulted in propagation of more than 1x108 cells
within a time period of 15 days from a single umbilical cord. The upscaled WJ-MSCs retained their differentiation potential
and immunosuppressive capacity. They expressed the typical hMSC surface antigens and the addition of bFGF in the culture
medium did not affect the expression levels of HLA-DR and CD 44. A normal karyotype was confirmed in the large-scale
expanded WJ-MSCs. Hence, in this study we attempted rapid clinical-scale expansion of WJ-MSCs which would allow these
fetus-derived stem cells to be used for various allogeneic cell-based transplantations and tissue engineering.
© 2010 Elsevier B.V. All rights reserved.Introduction
Mesenchymal stem cells or multipotent stromal cells (MSCs) are
adult mulitpotent cells which have been isolated from almost
every type of connective tissue (da Silva Meirelles et al., 2006).
They can self-renew and under appropriate in vitro conditions
have the capacity to differentiate into mesodermal, endoder-
mal, and even ectrodermal lineages (Pittenger et al., 1999;
Lakshmipathy and Verfaillie, 2005). They evoke only minimal⁎ Corresponding author. Manipal Institute of Regenerative Medi-
cine, Manipal University, 10, Service Road, Domlur Layout, Airport
Road, Bangalore 560 071, India. Fax: +91 80 25356662.
E-mail address: malancha.ta@manipal.edu (M. Ta).
1873-5061/$ – see front matter © 2010 Elsevier B.V. All rights reserved
doi:10.1016/j.scr.2010.08.005immunoreactivity (Tse et al., 2003) and secrete bioactive
factors with anti-inflammatory and immunomodulatory effects
in vivo (Le Blanc, 2003; Caplan and Dennis, 2006). Hence, MSCs
appear to have a remarkable clinical potential in tissue
regeneration and immunoregulatory therapeutic applications.
MSCs were first identified by Friedenstein and his
colleagues as fibroblast-like cells with clonogenic potential
residing in rat bone marrow (Friedenstein et al., 1966). To
date, the best characterized source of MSCs is the bone
marrow (BM) and most of the knowledge regarding MSCs is
based on BM studies. However, processing and harvesting of
MSCs from BM has certain limitations such as being a highly
invasive procedure to the donors and there is a sharp
decrease in number of MSCs per nucleated marrow cell with
age. Again, the multipotent differentiation potential and
proliferation efficiency of BM-MSCs decline with increasing.
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There are now various other sources of MSCs and one such
alternative source is the umbilical cord which, though a fetus-
derived tissue, can be easily obtained and processed and is
noncontroversial. Wharton's jelly (WJ) is the connective tissue
between the umbilical cord vessels and WJ-derived MSCs
possess multipotent properties between embryonic stem cells
and adult stem cells (Bongso et al., 2008). They have a higher
proliferation rate and self-renewal capacity compared to adult
stem cells (Can and Karahuseyinoglu, 2007). Thus, WJ-MSCs
have the potential to act as cellular therapy in transplantation
and regenerative medicine.
MSCs are currently being used in a number of animalmodels
for human diseases and tested in several clinical trials
(Schwarz et al., 1999; Schwarz et al., 2001; Ringden et al.,
2006; Mazzini et al., 2006; Koc et al., 2002; Numaguchi et al.,
2006). However, MSC transplantation requires harvesting a
large number of cells. They are present in very low percentages
in their niches and a vast number of cells are required to
provide sufficient quantity for subsequent therapeutic applica-
tions. MSC seeding density as well as choice of medium and
type of tissue culture plastic can influence cell proliferation
(Sotiropoulou et al., 2006). It has been reported previously that
human cells proliferate most rapidly and maximally retain the
multipotentiality when seeded at low densities (Colter et al.,
2000; Sekiya et al., 2002). Basic fibroblast growth factor (bFGF)
is a well-established growth factor which can enhance cell
proliferation. There are reports of bFGF being used as a potent
mitogen for MSCs in culture while maintaining their differenti-
ation potential and telomere length (Van den Bos et al., 1997;
Tsutsumi et al., 2001). That MSCs enter senescence almost
undetectably from the moment of in vitro culturing was
reported earlier and hence, it is much better to consider them
for cell and gene therapy early on (Bonab et al., 2006). Again,
large-scale in vitro expansion may lead to genetic and
epigenetic instabilities. Although, human MSCs are not prone
to spontaneous transformations and quite a few reports suggest
normal karyotypes and DNA copy numbers in long-term cultures
of MSCs (Tonti and Mannello, 2008), emergence of tumorogenic
populations on in vitro culture of bone marrow human MSCs has
been described (Wang et al., 2005).
We had earlier described a protocol for upscaling WJ-MSCs
and attaining 4–5×109 cells in 5–6 passages from a single cord
(Nekanti et al., 2010). Here, we modified and optimized the
protocol for the large-scale production of WJ-MSCs which
reproducibly resulted in more than 1×108 cells from a single
umbilical cord by passage 1 or within 15 days. We have
analyzed the multilineage differentiation behavior and cell
surfacemarkers of the upscaledMSCs. In addition, the upscaled
WJ-MSCs expressed the mesenchymal stem cell/progenitor
marker STRO-1 and the pluripotency marker OCT-4. To exclude
the possibility that large-scale expansion can affect immuno-
suppressive ability, the influence of upscaled WJ-MSCs on
PHA-driven lymphocyte proliferation was determined. Karyo-
type analysis was performed to evaluate numerical and
structural abnormalities, if any, in the large-scale expanded
WJ-MSCs and also, they were assessed for the expression of
oncogenes and tumor-suppressor genes.
Hence, here we present optimal culture conditions to
generate clinical quantities of human WJ-derived MSCs with
retained differentiation potential, immunosuppressive ca-
pacity, and chromosomal stability.Results
Experiments were carried our using three separate sets of
WJ-MSC samples. The first set was used to standardize seeding
density, the second set was used to establish bFGF concentra-
tions, and the third set was used to conduct the clinical-scale
expansion.
Effect of seeding density and bFGF on expansion of
WJ-MSCs
A standardized procedure was utilized to isolate WJ-MSCs from
termumbilical cord (Nekanti et al., 2010). To compare different
seeding densities, WJ-MSCs, isolated from three different
umbilical cord samples, were plated at 1000, 2000, 3000, and
5000 cells/cm2. Next they were cultured in DMEM-KO supple-
mented with 10% FBS for eight passages and total cell numbers
were plotted (Fig. 1A). Low density culture at 1000 cells/cm2
took 34 days while high density culture at 5000 cells/cm2 took
18 days to complete eight passages. At the end of eight
passages, maximum cell numbers of 4.15×1013±2.59×1013
and 2.72×1010±8.26×109 (Fig. 1A) corresponding to cumulative
population-doubling peaks of 31.39±0.87 and 18.93±0.40
(Pb0.001, data not shown) were attained by 1000 and 5000
cells/cm2, respectively. Passaging density affected WJ-MSCs’
proliferation potential and lower densities resulted in higher
proliferation rates. The mean of population doublings (PD) at
each subcultivationwas plotted and an increase in number of PD
resulted from reducing the initial seeding density. Seeding
densities of 5000 and 1000 cells/cm2 corresponded to 2.36±0.05
and 3.92±0.11 mean PDs (Pb0.001), respectively (Fig. 1B).
Next WJ-MSCs (n=4) were plated at 1000 cells/cm2 with 10%
FBS, plain or supplementedwith 2 and 4 ng/ml bFGF. Cells were
cultured for five passages under the respective culture
conditions. Supplementation of WJ-MSC culture media with
bFGF increased the proliferation rate. The optimal condition
was represented by 2 ng/ml bFGF. After five passages we
obtained 5.17×109±7.89×108 and 9.64×1010±4.02×1010 ex-
panded MSCs (data not shown) corresponding to mean PD times
of 26.44±1.22 and 20.01±0.32 h (P=0.0027) for no bFGF and
2 ng/ml bFGF-treated cultures, respectively. WJ-MSCs treated
with 2 ng/ml of bFGF displayed higher cumulative population
doublings reaching apeak of 22.68±0.75 compared to untreated
WJ-MSCs with a peak of 18.92±0.25 (P=0.006) at passage 5. No
additional significant increase in cumulative PD (PN0.05) or
mean PD time (PN0.05) was attained at the end of five passages
by further increase in the bFGF concentration from 2 to 4 ng/ml
(Figs. 1C and D).
Based on these experimental results, a seeding density of
1000 cells/cm2 and 2 ng/ml bFGF were selected for the
subsequent experiments.
Clinical-scale expansion procedure
MSC cultures were successfully established from five umbilical
cord samples. After isolation, WJ-MSCs were plated without
counting into a T75 flask in DMEM-KO supplemented with 10%
FBS and 2 ng/ml bFGF. After 9–10 days of primary culture, cells
were counted and reseeded at 1000 cells/cm2 onto 2 Cell-
STACKS for clinical-scale expansion under the same medium
conditions, guided by the previously described experiments.
Figure 1 Effect of seeding density and basic fibroblast growth factor (bFGF) supplementation of growth medium on growth kinetics of
WJ-MSCs. Comparison of the influence of WJ-MSC seeding density of 1000, 2000, 3000, and 5000 cells/cm2 on (A) cell proliferation. (B)
Population doublings. Data are expressed asmean±SEM.Data represent analysis from three independently performed experiments (n=3).
Comparison of the effect, without and with 2 and 4 ng/ml, of bFGF supplementation on (C) cumulative population doublings per passage
and (D) average population-doubling time. Results represent the average of four culture replicates (n=4)with SEM. * Significant difference
at Pb0.05. ** Significant difference at Pb0.01. *** Significant difference at Pb0.0001.
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the clinical-scale cultures which corresponded todoubling time
of 22.93±0.94 h and underwent 5.80±0.27 PDs over the 5-day
culture period (Fig. 2A). Hence, primary culture (P0) was
followed by a second expansion step (P1) which is the clinical-
scale expansion step. A representative photograph of upscaled
WJ-MSC cultures is shown in Fig. 2C. Data of clinical-scale
expansions of individual WJ-MSC samples are shown in Table 1.
Toevaluate the clonal expansion capacity ofWJ-MSCs, CFU-F
assay was initiated using the P1 cells. As shown in Fig. 4 L,
WJ-MSCs displayed a CFU-F potential of 29.8±2.8.
A normal karyotype, as assessed by GTG banding, was
confirmed in large-scale expanded WJ-MSCs (Fig. 2D).Immunophenotype and immunofluorescent analysis
of upscaled WJ-MSCs
Flow cytometry revealed that the clinical-scale expanded
WJ-MSCs were positive for mesenchymal markers CD 44, CD
73, CD 90, CD 105, CD 146, and CD 166 and negative for
hematopoietic stem cell markers CD 34 and CD 45 and human
leukocyte antigen (HLA)-DR (Fig. 3).STRO-1 is a cell surface antigen which is expressed by
mesenchymal stromal progenitor cells (Gronthos et al., 1994;
Jones et al., 2002). The presence of STRO-1 (Fig. 4G) was
identified in upscaled WJ-MSCs by immunofluorescence. Also,
we detected a punctate nuclear staining for Oct-4 (Fig. 4H) in
these cells. Although OCT-4 is expressed almost exclusively in
embryonic stem cells (Suzuki et al., 1990), it has recently been
reported in porcine umbilical cord matrix cells (Carlin et al.,
2006) and in amniotic fluid cells (Prusa et al., 2003). HeLa cells,
which were used as a negative control, did not show any
observable staining for OCT-4 (Fig. 4J).In vitro differentiation potential of WJ-MSCs after
clinical-scale expansion
We further investigated if the large-scale expansion had an
impact on the in vitro differentiation potential of the
WJ-MSCs. We subjected the upscaled WJ-MSCs to adipo-
genic, osteogenic, and chondrogenic differentiation. Induc-
tion of osteogenesis in the upscaled WJ-MSCs resulted in
extracellular matrix mineralization which was confirmed by
Von Kossa staining (Fig. 4B) while adipogenic differentiation
Figure 2 Clinical-scale expansion of WJ-MSCs. (A) Plan of the experiment. After enzymatic digestion of human umbilical cords
(n=5), cells were plated on T75 flasks for primary culture. In the next step, clinical-scale expansions of WJ-MSCs were initiated in 2
CellSTACK chambers at a seeding density of 1000 cells/cm2 in the presence of 2 ng/ml of bFGF. 2.48±1.43×108 cells were harvested
after a total of 15–16 days. (B) Large-scale expansion of WJ-MSCs within a single passage (or 5-day culture period) using a 2 CellSTACK
chamber. Result represents the average of five culture replicates with SEM. (C) Representative phase-contrast images of WJ-MSC
showing morphology after clinical-scale expansion. Scale bar =50 μm. (D) G-banded karyotype of upscaled WJ-MSCs. Representative
result of three independent experiments is shown.
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positive for oil red O staining (Fig. 4D). Positive staining of
Alcian blue indicated that upscaled WJ-MSCs could differen-
tiate to chondrocytes (Fig. 4F). No staining was seen in














WJ 1 1.39×106 1.27×106 7.44×107 15.5
WJ 2 1.22×106 1.22×106 5.30×107 15.5
WJ 3 4.41×106 1.27×106 1.88×108 15.5
WJ 4 7.13×106 1.27×106 8.13×108 15.5
WJ 5 2.40×106 1.27×106 1.13×108 14.5
At P1 WJ-MSCs were plated on 2 CellSTACK chambers at 1000
cells/cm2.Suppression of mitogen-induced T-cell proliferation
by the upscaled WJ-MSCs
To evaluate if the clinical-scale-propagatedWJ-MSCs can affect
the proliferation of T cells in PBMCs in vitro, PHA-activated
PBMCs were incubated with and without a layer of mitomycin
C-arrested WJ-MSCs. T-cell proliferation was inhibited when
cocultured with WJ-MSCs and the degree of inhibition was
directly proportional to the number ofWJ-MSCs in the coculture
(Fig. 4K). The data demonstrated that clinical-scale-propagated
WJ-MSCs could suppress T-cell proliferation efficiently.
Semiquantitative evaluation by RT-PCR
Upscaled WJ-MSCs at P1 were tested for the presence of the
hTERT gene by RT-PCR. No expression was detected (Fig. 5C).
Myc, p53, p21, and p16 expression has been involved in MSC
transformation (Tarte et al., 2010) and hence, we compared
the mRNA expression levels of p53, p21, p16, and c-Myc in
corresponding P0 and P1 (upscaled) passages of the same
WJ-MSC samples (Fig. 5A). Our results revealed no change in
expression levels for p53, p21, p16, and c-Myc, betweenP0and
Figure 3 Immunophenotype of upscaled WJ-MSCs as analyzed by flow cytometry. Representative flow cytometry analysis of
WJ-MSCs (n=5) after clinical-scale expansion when labeled with antibodies against human antigens CD 90, CD 73, CD 44, CD 146, CD
105, CD 34, CD 45, and HLA-DR. Open histogram indicates background signal; shaded histogram represents positive reactivity with the
indicated antibody.
248 U. Nekanti et al.P1 upscaled WJ-MSCs, in two out of three samples tested. In
the third sample, all the above-noted four genes were
upregulated after scale-up, i.e., at P1. P0 and upscaled P1
cells were examined for OCT-4 expression by RT-PCR (Fig. 5B).
Except for one sample, where there was an increase, the other
two maintained the mRNA level of OCT-4 at P1.Discussion
Due to their potential for self-renewal and multilineage
differentiation potential, MSCs represent a major hope for
cell-based therapy and tissue engineering. Again because of
their immunomodulatory properties, MSCs can provide
clinical benefit toward the treatment of several autoimmune
disorders and graft versus host disease. MSCs have been
recently isolated from several fetal tissues such as amniotic
fluid, placenta, amnion, umbilical cord blood, and Wharton's
jelly of the umbilical cord. The umbilical cord is discarded as
a medical waste after birth and therefore, both technically
and ethically, UC represents a source of MSCs which is readilyaccessible. Recently umbilical cord was reported to be a
richer source of MSCs than umbilical cord blood (Secco et al.,
2008). Also, WJ cells exhibited better rescue of photorecep-
tors and visual functions as compared to placental stem cells
and bone marrow MSCs (Lund et al., 2007). They originate
from the embryonic epiblast and retain a combination of
most of the embryonic stem cell and MSC markers in primary
culture and early passages (Bongso et al., 2008). WJ-MSCs
have been shown to be therapeutic in several different
preclinical animal models of human disease (Troyer and
Weiss Wharton's, 2008). However, to meet the clinical
demand, it is important to establish a procedure for
generation of sufficient quantity of clinical-grade WJ-MSCs
in vitro within a reasonable time frame.
Recently, we demonstrated the superiority of DMEM-KO in
supporting the in vitro expansion of WJ-MSCs, and could
expand WJ-MSCs from a single cord to 4-5×109 cells in 5–6
passages at a seeding density of 5000 cells/cm2 (Nekanti et al.,
2010). As, MSCs lose their stemcell characteristicswith in vitro
culturing, it is better to use them for cell and gene therapy
early on (Bonab et al., 2006). In the present study, using a
Figure 4 Differentiation capacity of WJ-MSCs after clinical-scale expansion. WJ-MSCs derived after clinical-scale expansion were
induced to differentiate along (B) osteogenic (Von Kossa staining) (D) adipogenic (oil red O staining) and (F) chondrogenic (Alcian blue
staining) lineages. (A, C, E) Corresponding uninduced control cultures were stained for comparison. Representative results of three
independent experiments are shown. Expression ofmesenchymal progenitor cellmarker STRO-1 and pluripotencymarkerOct-4 (Octamer-
4 homeodomain transcription factor) in upscaled WJ-MSCs by immunofluorescence. Positive staining (green) for (G) STRO-1 on the cell
surface and (H) punctuateOct-4 staining in thenucleuswhichwas undetectable in control secondary antibody only sample (I). (J) HeLa cell
line was used as negative control for Oct-4 staining. Inset: Nuclei were stained with DAPI (blue). Representative results of three
independent experiments are shown. Scale bar =50 μm. (K) PHA-induced proliferation of T cells in PBMCs in the absence and presence of
different numbers ofMSCswas evaluatedbyMTTassay.MTT assayswereperformed in triplicate and the resultswereaveraged. Results are
representative of four independent experiments. (L) Representative images, from three independently performed experiments, of
9-day CFU-F colonies initiated from P1 WJ-MSCs.
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the WJ-MSC seeding density from 5000 to 1000 cells/cm2
resulted in an increase in proliferation. Therefore, our results
indicate that even in the case of WJ-MSCs, there is an inverse
correlation between seeding density and population dou-
blings. A seeding density of 1000 cells/cm2 resulted in
significantly higher population doublings when compared to
2000, 3000, or 5000 cells/cm2. We also demonstrated that
supplementation of culture medium with 2 ng/ml of bFGF
resulted in greater proliferative capacity of the WJ-MSCs.
bFGF has been used in therapeutic angiogenesis and shown to
be safe and well tolerated in human trials (Aviles et al., 2003;
Laham et al., 2000; Ito et al., 2008), and besides, cells would
bewashedwithDPBSbefore theyare injected for preclinical orclinical studies. A significant gain in cumulative population
doublings resultedwhen including 2 ng/ml bFGF to the culture
medium. Increasing the bFGF concentration further, from 2 to
4 ng/ml did not make any significant difference to population
doublings or population-doubling time. Hence, using a seeding
density of 1000 cells/cm2 and including 2 ng/ml bFGF in the
culture medium which is DMEM-KO, we next expanded
WJ-MSCs to a clinical quantity of~108 cells within approxi-
mately 15 days or passage 1.
An extensive characterization of cell surface marker
expression using flow cytometry revealed that the upscaled
WJ-MSCs were positive for representative MSC markers such
as CD 44, CD 73, CD 90, and CD 105. Recent investigations
suggest that MSCs are found as perivascular cells or pericytes
Figure 5 RT-PCR analysis of hTERT,OCT-4, and tumor-suppressor genes. (A, B) RelativemRNAexpression levels of OCT-4, c-Myc, p53, p21,
and p16, analyzed by RT-PCR, were compared between P0 and P1 upscaled cultures of WJ-MSCs. cDNA from HeLa cell line was used as a
positive control for p16 PCR. (C) hTERT expression was not detected in upscaled WJ-MSCs using PCR primers specific for the hTERT gene.
NTERA-2, known to express hTERT, was used as a positive control. 18 s ribosomal RNA was used as an internal control. Results of all three
independent experiments are shown.
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expression of CD 146, an endothelial cell antigen also
expressed on the surface of pericytes, in the upscaled WJ-
MSCs. The use of bFGF in human BM-MSC cultures resulted in
upregulation of HLA-DR along with downregulation of CD44
expression (Sotiropoulou et al., 2006). Our results demon-
strated that the upscaled WJ-MSCs were strongly positive for
CD44 while they were negative for HLA-DR, suggesting that
bFGF at 2 ng/ml did not affect the expression levels of CD44
or HLA-DR in WJ-MSCs. The upscaled WJ-MSCs also confirmed
the expression OCT-4 transcription factor at mRNA as well as
protein level and STRO-1, a marker for mesenchymal
progenitor cells, at the protein level as detected by
immunofluorescence. We further found that the upscaled
WJ-MSCs retained multilineage potentiality and could be
induced to undergo subsequent adipogenic, osteogenic, and
chondrogenic differentiation. They could effectively sup-
press mitogen-induced T-cell proliferation and also did not
bear any chromosomal abnormalities, as assessed by karyo-
type analysis. Telomerase promotes MSC immortalization
and along with other events such as amplified c-Myc
expression and accumulated chromosomal abnormalities
can result in cell transformation (Miura et al., 2006). Changes
in tumor suppressor and oncogene expression have been linked
with murine MSC transformation (Rodriguez et al., 2009).
hTERT expression was undetectable in the upscaled WJ-MSCsat the end of passage 1.OncomparingP0and upscaledP1 cells,
we observed an increase in p16 expression in a few of the WJ
samples at P1 which could possibly suggest replicative
senescence (Tarte et al., 2010). Therefore, although WJ-MSCs
are not known to produce teratomas in immunodeficientmice,
it is important to test all clinical-grade MSC samples for in vivo
tumorogenesis in animals before they are planned for
therapeutic applications.
This is the first report of clinical-scale expansion of
WJ-MSCs from a single umbilical cord to quantities of more
than 108 cells within about 2 weeks. In fact, by adding just one
more round of expansion, we should be able to generate
sufficient quantities of MSCs to treat ~50 patients from a single
cord, considering that a 75-kg patient needs approximately
2×106 MSCs per killigram body weight for transplantation
(Bartmann et al., 2007), though an optimal MSC dose needs to
beevaluated for the different indications. Froma clinical point
of view, as this simple procedure does not involve repeated
passaging ormanipulation, it would bring down the production
cost of the “cell drug.”
Thus, WJ of umbilical cord may represent a significant
alternative source of MSCs for allogeneic cell-based thera-
pies with distinct advantages, such as easy accessibility, no
ethical concerns, and painless procedure to donors. For
clinical use, pooling of MSCs from three to five different
umbilical cords could be envisioned, as merging MSCs from
251Clinical-scale expansion of WJ-MSCsdifferent donors would assure constant cell quality and
availability (Dahlke et al., 2008) along with improved
immunosuppressive function (Samuelsson et al., 2009).
Since the ideal clinical-scale propagation of MSCs would
involve the use of animal protein-free defined culture
medium, we had attempted propagation of WJ-MSCs in
knockout serum replacement (KoSR) as an alternative to
replace FBS (Nekanti et al., 2010). Unfortunately, KoSR did
not support the growth of WJ-MSCs. In fact, serum-free
medium without the addition of growth factors is, usually,
not able to expand MSCs in vitro. Platelets are a rich source
of growth factors and the use of pooled human platelet
lysate as an alternative to FBS has been investigated for FBS-
free propagation of MSCs (Tonti and Mannello, 2008; Reinisch
et al., 2007). Hence, a thorough clinical investigation of
which is best, amongs FBS, human serum, or human platelet
lysate, needs to be attempted. Currently efforts are on in our
laboratory to make our cell drug animal-product free.
Materials and methods
Isolation and culture of WJ-MSCs
Human umbilical cords (n=15) from both sexes were
collected from full-term births after either cesarean section
or normal vaginal delivery with informed consent using the
guidelines approved by the Institutional Committee for Stem
Cell Research and Therapy (ICSCRT) and Institutional Ethics
Committee (IEC) at the Manipal Hospital, Bangalore, India.
WJ-MSCs were isolated as previously described (Wang et al.,
2005).
For optimization of cell seeding density, WJ-MSCs from
three different umbilical cords (n=3) were plated at passage
1 (P1) on tissue culture plastic plates (BD Biosciences, San
Jose, CA; USA) at 1000, 2000, 3000, and 5000 cells/cm2 in
Knock out Dulbecco's modified Eagle's medium (DMEM-KO)
(Invitrogen, CA, USA), supplemented with 10% FBS (Hyclone,
Victoria, Australia) and 2 mM L-glutamine (Invitrogen). The
same lot of serum (Cat. No.SH30084.03, Lot No. GQM0049)
was used for all the experiments. For basic fibroblast growth
factor optimization experiment, isolated WJ-MSCs from
individual cord samples were plated at P1 at defined seeding
density of 1000 cells/cm2 in DMEM-KO with 10% FBS, plain or
supplemented with 2 or 4 ng/ml bFGF (Sigma, MO, USA).
Cultures were incubated at 37 °C with 5% humidified CO2. At
~70–80% confluence, cultures were trypsinized with 0.05%
trypsin/0.53 mM EDTA (Invitrogen). For upscaling experi-
ments, harvested cells at P0 were seeded at density of 1000
cells/cm2 on 2 CellSTACK chambers (Corning, NY, USA)
supplemented with DMEM-KO, 10% FBS, 2 mM L-glutamine,
and 2 ng/ml bFGF. On Days 5–6 (at 70–80% confluence) cells
were harvested and used for subsequent studies. Additional
aliquots were cryopreserved.
Growth kinetics
Growth kinetics was analyzed by calculating population
doubling and population-doubling time. Population doublings
were calculated using the formula: X=[log10(NH) – log10
(NI)]/log10(2) where NI is the inoculum cell number and NH
the cell harvest number. The cumulative population-dou-bling level was calculated by adding the population doubling
for each passage to the population-doubling level of the
previous passage.
The population-doubling time was obtained by the
formula: TD=tplg2/(lgNH–lgNI). NI is the inoculum cell
number, NH is the cell harvest number, and t is the time of
the culture (in hours).
Immunophenotyping
WJ-MSCs expanded in 2 CellSTACK chambers were taken for
flow cytometric analysis. The following anti-human anti-
bodies were used to mark the cell surface markers: CD90-PE,
CD73-PE, CD44-PE, CD 146-PE, CD166-PE, CD34-PE, CD45-
FITC, and HLADR-FITC (all from BD Pharmingen, CA, USA) and
CD105-PE (R&D systems, MN, USA). Mouse isotype antibodies
served as control (BD Pharmingen). The number of cells
staining positive for a marker was determined by the
percentage of cells present within a gate established such
that 3% of the positive events measured represented
nonspecific binding by the PE or FITC-conjugated isotype-
matched control. At least 10,000 events were acquired on BD
LSR II flow cytometer and the results were analyzed using
WIN MDI v2.8 software.
Differentiation
In vitro differentiation of WJ-MSCs after clinical-scale expan-
sion was performed as previously described (Wang et al.,
2005). In brief, osteogenic differentiation was induced in the
DMEM-KO media supplemented with 10% (vol/vol) FBS
(Hyclone), 2 mM L-glutamine (Invitrogen), 0.1 μM dexametha-
sone, 10 mM β-glycerophosphate, 0.2 mM ascorbic acid (all
reagents from Sigma Aldrich). Mineralized deposits were
visualized by Von Kossa staining after 21 days. Cells were
fixed with 4% paraformaldehyde (Sigma Aldrich) for 20 min
and exposed to 1% silver nitrate (Merck) under bright light
for 60 min. Adipogenic differentiation was initiated in
DMEM-KO/10% FBS/2 mM glutamine supplemented with
200 μM indomethacin, 0.5 mM 3-isobutyl-1-methylxanthine,
10 μg/ml insulin, and 1 μM dexamethasone (all reagents from
Sigma Aldrich). At Day 18, the presence of lipid droplets was
confirmed by oil red O stain (Sigma Aldrich) and the nuclei were
counterstained with hematoxylin. Chondrogenic differentiation
was induced in confluentmonolayer cultures ofWJ-MSCs using a
STEMPRO chondrogenesis differentiation kit (Invitrogen). Dif-
ferentiated cells were stained with Alcian blue 8GX (Sigma)
between 8 and 14 days. Images were captured using a Nikon
Eclipse TE2000-U inverted microscope (Nikon, Tokyo, Japan).
Immunofluorescence staining
Upscaled WJ-MSCs at passage 2 were plated on chamber-
slides (BD Falcon). Next they were fixed in 4% paraformal-
dehyde (Sigma) for 20 min at room temperature and
permeabilized in 0.3% Triton X-100. After blocking in 10%
normal rabbit serum/goat serum (Sera Laboratories Interna-
tional Ltd, West Sussex, UK), the cells were incubated with
primary antibodies, goat anti-Oct-4 (1.6 μg/ml, R&D Sys-
tems), and mouse anti-STRO-1 (10 μg/ml, R&D Systems).
Secondary antibodies used were FITC-conjugated rabbit anti-
252 U. Nekanti et al.goat IgG and FITC-conjugated goat anti-mouse IgM (1:250,
Chemicon, Temecula, CA, USA). For negative control
sample, the primary antibody was omitted. Slides were
counterstained with 4′,6′-diamidino-2-phenylindole dihy-
drochloride (DAPI) for 5 min. Fluorescent images were
captured using a Nikon-Eclipse-90i microscope (Nikon) and
Image-Pro AMS version 6.0 software.
Immunosuppression assay
Upscaled WJ-MSCs were treated with 10 μg/ml mitomycin C
(Sigma Aldrich) for 2 h and 30 min at 37 °C to inhibit MSC
proliferation followed by 5 washes with DMEM-KO medium.
The cells were next trypsinized and plated in triplicates onto
96-well plates at 12,500, 6250, 3125, and 1562 cells/well.
Peripheral blood mononuclear cells (PBMCs) were isolated by
density gradient centrifugation. PBMCs were stimulated with
10 μg/ml phytohemagglutinin (PHA, Sigma Aldrich) and
2×105 activated PBMCs were added per well. PHA-activated
PBMCs were cultured in the presence and absence of WJ-
MSCs. Cultures were incubated at 37 °C, 5% CO2 for 72 h.




WJ-MSCs were collected after enzymatic digestion and
seeded, in 6-well tissue culture plates, at 10 cell/cm2 and
in triplicates from each of the three cord samples. After
9 days cells were washed with DPBS, fixed in 1% paraformal-
dehyde for 20 min, stained with 0.1% toluidine blue (in 1%
formaldehyde solution) for 1 h, and then rinsed in tap water.
Aggregates of 50 cells or more were defined as CFU-Fs. Data
are reported as total colony number per 100 cells.
Karyotype analysis
Karyotyping of upscaled WJ-MSC was carried out using a
standard Giemsa staining procedure. At least 20 metaphase
spreads were analyzed from each MSC preparation. Images
were acquired using a Nikon-Eclipse-90i microscope (Nikon).
RT-PCR analysis
Total cellular RNA was isolated using a mirVana miRNA
isolation kit (Ambion, Austin, TX). To eliminate traces of
genomic DNA, the RNA samples were treated with DNA-free
DNase I (Ambion)) according to the manufacturer instruc-
tions. The RNA was reverse-transcribed into cDNA using a
High Capacity cDNA reverse transcription kit (Applied
Biosystems). PCR amplification was performed using Taq
polymerase (Sigma) by following standard procedures. The
primer sequences were as follows: hTERT, forward primer,
5′-CCTGCTCAAGCTGACTCGACACCGTG and reverse primer, 5′-
GGAAAAGCTGGCCCTGGGGTGGAGC-3′-3′ (446 base pairs [bp]);
c-Myc, forward primer, 5′-AAGACTCCAGCGCCTTCTCTC-3′ and
reverse primer, 5′-GTTTTCCAACTCCGGGATCTG-3′ (526 bp);
P16, forward primer, 5′-TTATTTGAGCTTTGGTTCTG-3′ and
reverse primer, 5′-CCGGCT TTCGTAGTTTTCAT-3′ (354 bp);P21, forward primer, 5′-GAGGCCGGGATGAGTTGGGAGGAG-3′
and reverse primer, 5′-CAGCCGGCGTTTGGAGTGGTAGAA-3′
(220 bp); P53,forward primer, 5′-TTGGATCCATGTTTTGC-
CAACTGGCC-3′ and reverse primer, 5′-TTGAATT-
CAGGCTCCCCTTTCTTGCG-3′ (488 bp); OCT-4, forward
primer, 5′-CGACCATCTGCCGCTTTGAG-3′ and reverse primer,
5′-CCCCCTGTCCCCCATTCCTA-3′ (577 bp); 18 s rRNA, forward
primer, 5′-CGGCTACCACATCCAAGGAA-3′ and reverse primer,
5′-GCTGGAATTACCGCGGCT-3′ (186 bp).
Statistical data analysis
Data are presented as mean±SEM. Comparisons of continu-
ous variables between more than two groups were performed
by one- or two-way ANOVA, as applicable, and Bonferroni′s
multiple comparison test. Student's t test was performed for
comparison of pairs of groups. The cutoff value for
significance was 0.05. Data analysis and graphical represen-
tations were performed by using GraphPad Prism 5 software
(GraphPad, San Diego, CA, USA).
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